Secarna Pharmaceuticals GmbH:
LNAplus™ based antisense therapies have the potential to demonstrate superior safety and efficacy benefits over other modalities in development and on the market.
Secarna's uniquely efficient LNAplus™ discovery process is fueled by their proprietary and streamlined Oligofyer™ bioinformatics systems large in-house cell library and
own in vitro screening assays.
For subsequent pre-clinical development, Secarna's molecule design and selection work is complemented by partnerships with internationally renowned centers of excellence across academia and industry.
Am Klopferspitz 19
Planegg, Bayern 82152
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.